German Centre for Cardiovascular Research Cardiomyopathy Register (TORCH)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02187263|
Recruitment Status : Unknown
Verified March 2016 by Heidelberg University.
Recruitment status was: Recruiting
First Posted : July 10, 2014
Last Update Posted : March 25, 2016
This is a joint project by Heidelberg University and Greifswald University.
Our objective is to establish an unique national multi-center registry and biobank of well phenotyped patients with non-ischemic cardiomyopathies (CMP) including in depth clinical, molecular and omics-based phenotyping to serve as:
- central hub for clinical outcome studies.
- joint resource for diagnostic and therapeutic trials.
- common biomaterial bank.
- resource for detailed molecular analyses on patients' biomaterials and patient specific model systems.
|Condition or disease|
|Acute Myocarditis Dilated Cardiomyopathies Hypertrophic Cardiomyopathies Left Ventricular Myocardial Noncompaction Cardiomyopathy Arrhythmogenic Right Ventricular Cardiomyopathies Amyloidosis|
The following basic research projects, called modules, will be tied to and rely on the recruitment of CMP patients and the infrastructure provided by TORCH:
- Well phenotyped patients will be the starting point for comprehensive next-generation genotyping, leading to advanced estimates of genotype-phenotype relationship and its clinical impact.
- Functional analysis of novel genomic loci and their related molecular pathways will be based on our established in-vitro (e.g. iPS cells, yeast two hybrid) and in-vivo (e.g. zebrafish and mice) model systems.
- The integrated analysis of viral load and replication, inflammation, genotype and clinical variables will define risk variables for inflammatory and hereditary CMP.
- By longitudinal follow-up of patients, the role of genetic, epigenetic, metabolic, molecular biomarkers and histopathology for diagnosis and out-come prediction will be defined on a national level.
The registry will also facilitate investigator initiated clinical trials.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||2300 participants|
|Target Follow-Up Duration:||12 Months|
|Official Title:||DZHK TranslatiOnal Registry for CardiomyopatHies Deutsches Zentrum für Herz- Und Kreislauf-Forschung (DZHK)|
|Study Start Date :||December 2014|
|Estimated Primary Completion Date :||December 2016|
|Estimated Study Completion Date :||December 2017|
- Time to Disease Progression [ Time Frame: 12 months ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02187263
|University of Heidelberg||Recruiting|
|Contact: Andreas O Doesch, MD 49 622156 ext 39936 Andreas.Doesch@med.uni-heidelberg.de|
|Study Chair:||Hugo A Katus, MD||Heidelberg University|
|Study Chair:||Wolfgang Hoffmann, MD||Department for Community Medicine, University Medicine Greifswald|